Stock Analysis on Net

DexCom Inc. (NASDAQ:DXCM)

This company has been moved to the archive! The financial data has not been updated since October 26, 2023.

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

DexCom Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel
3 months ended: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net income (loss) 120,700 115,900 48,600 91,800 101,200 50,900 97,300 (19,400) 70,900 62,900 40,300 355,200 72,200 46,300 19,900 92,700 45,800 (10,500) (26,900) (179,700) 46,600 30,200 (24,200)
Depreciation and amortization 48,200 43,700 41,600 36,300 39,200 43,600 36,800 32,100 25,500 23,500 20,900 20,400 18,400 15,300 13,000 14,300 12,900 11,600 9,900 8,600 7,800 6,700 6,000
Share-based compensation 39,000 39,700 35,200 34,000 30,800 32,600 29,100 26,300 27,500 31,600 28,000 34,100 30,700 30,700 23,900 23,600 24,400 29,700 25,000 24,600 27,100 25,600 24,600
Collaborative research and development fee 87,100
Loss on extinguishment of debt 700 800 500 5,400
Non-cash interest expense 2,200 2,100 1,500 1,600 1,500 1,600 1,600 22,000 22,000 22,500 22,200 22,000 21,700 17,600 12,700 12,600 12,500 12,300 12,200 6,600 3,800 3,800 3,700
Non-cash collaborative research and development fee through issuance of common stock 217,700
Unrealized gain on equity investment 4,800 9,300 (42,700) (7,400)
Realized (gain) loss on equity investment (1,000) (200) (11,600) 4,200 (44,100)
Deferred income taxes (85,000) (42,200) (9,300) 32,000 (33,800) (19,900) 100 (5,100) 100 400 (300) (277,300) 200
Other non-cash income and expenses (17,900) (15,700) (13,700) 2,800 15,900 12,200 3,800 13,100 14,500 8,000 8,000 8,200 2,000 3,400 100 1,300 2,500 (2,200) 300 (300) 300 5,600 (900)
Accounts receivable, net (35,800) (113,700) 76,600 (148,300) (4,500) (17,000) (30,100) 15,100 (35,700) (40,000) (14,900) (58,500) (73,400) 4,300 (14,700) (50,800) (18,400) (12,300) 21,500 (57,000) (8,100) (38,800) 10,700
Inventory (78,600) (55,400) (59,600) 5,700 26,900 1,100 15,600 (6,000) (21,700) (29,500) (55,000) (33,600) (35,400) (23,300) (22,200) 600 (2,500) (16,800) (30,400) (15,500) (9,000) 5,400 (6,400)
Prepaid and other assets 16,600 10,000 (13,400) (50,400) 1,300 15,400 (97,900) (3,100) 8,900 (6,900) (20,200) 9,400 14,800 (19,000) (7,600) (6,700) 1,800 2,900 (5,200) 400 1,600 (2,300) (2,700)
Operating lease right-of-use assets and liabilities, net (2,300) (1,400) (700) 300 (2,700) (2,500) (900) (1,200) 400 700 500 (100) (800) (400) (300) (1,000) (900) (200)
Accounts payable and accrued liabilities 219,500 190,300 86,700 123,800 75,300 42,500 53,500 (57,300) 115,300 (30,000) 30,000 67,900 69,800 51,500 5,300 30,800 24,300 28,400 25,500 6,000 17,300 30,700 2,200
Accrued payroll and related expenses 42,100 13,800 (39,300) 22,500 17,100 9,400 (40,500) 9,900 16,700 16,800 (33,000) 21,800 25,100 8,300 (29,100) 17,200 (2,800) 22,700 (21,100) 17,600 8,200 12,400 (14,400)
Deferred revenue and other liabilities 1,500 3,200 1,200 (19,600) 25,000 2,900 2,800 2,000 3,700 1,900 1,100 1,900 1,300 14,400 1,000 8,200 (5,000) (400) (3,000) (100) (4,000) 4,800 100
Changes in operating assets and liabilities 163,000 46,800 51,500 (66,000) 138,400 51,800 (97,500) (39,400) 86,000 (87,300) (91,300) 9,400 2,100 35,400 (67,700) (1,000) (3,600) 23,600 (12,900) (48,600) 6,000 12,200 (10,500)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities 148,500 74,400 106,800 40,700 192,000 121,900 (26,300) 125,200 176,400 (1,300) (12,500) (183,200) 75,400 107,800 (18,000) 51,000 48,700 75,000 38,700 213,400 10,200 11,200 15,500
Net cash provided by (used in) operating activities 269,200 190,300 155,400 132,500 293,200 172,800 71,000 105,800 247,300 61,600 27,800 172,000 147,600 154,100 1,900 143,700 94,500 64,500 11,800 33,700 56,800 41,400 (8,700)
Purchases of marketable securities (798,000) (1,340,300) (809,600) (868,600) (254,000) (597,200) (546,500) (932,900) (368,300) (369,900) (802,000) (915,100) (403,100) (1,374,200) (365,800) (473,600) (622,300) (883,800) (50,700) (112,500) (115,900) (192,100) (32,000)
Proceeds from sale and maturity of marketable securities 671,400 859,400 697,600 740,000 602,200 543,800 241,800 501,000 537,000 838,300 790,000 952,000 449,000 319,500 530,000 423,400 259,200 291,300 222,500 161,100 155,600 42,500 32,900
Purchases of property and equipment (50,400) (59,000) (74,700) (63,500) (108,200) (91,500) (101,600) (80,200) (108,100) (101,200) (99,700) (60,200) (47,400) (58,200) (33,200) (44,100) (49,700) (46,900) (39,300) (17,700) (23,800) (10,300) (15,300)
Acquisitions, net of cash acquired (700) (3,200) 1,400 (31,600) (11,300)
Other investing activities (2,500) (16,000) (2,000) (10,000) (2,300) 14,600 (4,000) (500) (700) (7,800) (2,400) (400) (1,200) (1,000)
Net cash (used in) provided by investing activities (179,500) (555,900) (186,700) (194,100) 229,300 (144,900) (411,800) (496,100) 29,000 363,200 (112,200) (24,000) (9,300) (1,115,300) 130,600 (94,300) (412,800) (639,400) 131,300 30,900 4,600 (159,900) (15,400)
Net proceeds from issuance of common stock 14,300 12,300 12,400 10,100 11,600 8,700 8,600 6,700 6,800 100 5,000 200 5,400 1,000 4,200
Purchases of treasury stock (188,700) (557,700) (100,000)
Proceeds from issuance of senior convertible notes, net of issuance costs 1,230,600 1,188,800 836,600
Repurchase of convertible notes (282,600)
Purchases of capped call transactions (101,300)
Payments for conversions of senior convertible notes (650,500)
Proceeds from sale of warrants 183,800
Purchase of convertible note hedge (218,900)
Other financing activities (1,200) (1,100) (1,100) (1,000) (7,200) (4,300) (4,800) (800) (800) (400) (7,900) (4,900) (4,100) (200) (200) (100) (800) (200) (100) (100) (1,800)
Net cash provided by (used in) financing activities (637,400) 939,500 11,200 (1,000) (552,500) (4,300) 5,300 (800) 10,800 (400) 800 (4,900) 4,500 906,000 6,500 (100) 6,000 (100) 4,900 701,600 5,400 (800) 4,200
Effect of exchange rate changes on cash, cash equivalents and restricted cash (3,500) (2,200) 1,100 6,800 (7,300) (4,300) (1,000) (500) (1,000) 500 (400) 1,300 1,000 300 (500) 1,000 (1,400) (900) 600 3,200 400 (900) (900)
Increase (decrease) in cash, cash equivalents and restricted cash (551,200) 571,700 (19,000) (55,800) (37,300) 19,300 (336,500) (391,600) 286,100 424,900 (84,000) 144,400 143,800 (54,900) 138,500 50,300 (313,700) (575,900) 148,600 769,400 67,200 (120,200) (20,800)

Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. DexCom Inc. net cash provided by (used in) operating activities increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. DexCom Inc. net cash (used in) provided by investing activities decreased from Q1 2023 to Q2 2023 but then increased from Q2 2023 to Q3 2023 exceeding Q1 2023 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. DexCom Inc. net cash provided by (used in) financing activities increased from Q1 2023 to Q2 2023 but then decreased significantly from Q2 2023 to Q3 2023.